Indeed, it is unclear that the clinical activity of proteasome inhibitors in MM, as well as that of IMiDs, which too have broad molecular specificity and can affect NF-κB signaling, is due to the inhibition of NF-κB (Staudt, 2010, Chen et al., 2011, McCurdy and Lacy, 2013). Here, NFKB1 is linked to Miyoshi myopathy.